Summary
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
History
Sol-Gel Technologies was founded in 2011 by a team of scientists, clinicians and business leaders in biomedical research. Since then, the company has developed its lead drug, telacekizumab, into a late-stage therapeutic product candidate for the treatment of moderate-to-severe psoriasis. The company has also developed a number of other therapeutic skin care products.
Mission
Our mission is to develop safe and effective treatments through innovative research and clinical development in order to improve the quality of life of patients with skin diseases.
Vision
Our vision is to be the leader in developing life-changing treatments for patients with skin diseases.
Key Team
Prof. David Avnir (Co-Founder)
Dr. Itzik Yosef (Chief Operating Officer)
Dr. Karine Neimann (VP of Projects & Planning and Chief Chemist)
Recognition and Awards
Sol-Gel Technologies has been recognized for its innovation with numerous awards, including Best Clinical Stage Biotech Company at the Patient-Focused Drug Development Conference in 2020 and Most Promising Company of the Year at the Annual Global Biotech Summit in 2019.
References
